Frankfurt
07.07.26 | 08:08
2,155 Euro
+0,47 % +0,010
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| OREXO Aktie jetzt für 0€ handeln | |||||
| 09.06. | Orexo AB: Orexo appoints Raheleh Nassaji as SVP Business Development, strengthening its focus on new partnerships | 131 | GlobeNewswire (Europe) | Uppsala, Sweden - June 9, 2026 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announced that the company is strengthening its business development efforts through the appointment of Raheleh Nassaji... ► Artikel lesen | |
| 19.05. | Orexo announces positive outcome from an in-vivo study of OX390 | 814 | PR Newswire | UPPSALA, Sweden, May 19, 2026 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces positive data from a pre-clinical in-vivo study on the nasal absorption of atipamezole... ► Artikel lesen | |
| 19.05. | Orexo AB: Orexo announces positive outcome from an in-vivo study of OX390 | 158 | GlobeNewswire (Europe) | Uppsala, Sweden - May 19, 2026 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces positive data from a pre-clinical in-vivo study on the nasal absorption of atipamezole when delivered with... ► Artikel lesen | |
| 07.05. | Orexo AB: Report from Orexo AB's annual general meeting May 7 2026 | 330 | GlobeNewswire (Europe) | Election of the board of directors and auditorThe annual general meeting in Orexo AB (publ) on 7 May 2026 resolved, in accordance with the nomination committee's proposal, that the number of board members... ► Artikel lesen | |
| 28.04. | Orexo AB: Orexo Q1 2026 Interim Report | 147 | GlobeNewswire (Europe) | Well positioned to advance pipeline to value inflection pointsFinancial summary January - MarchTotal net revenues of SEK 5.0 m (13.2)Net earnings for the period is SEK -105.2 m (-90.6)Cash flow for... ► Artikel lesen | |
| 06.03. | Invitation & Agenda: Orexo R&D Day on March 24 | 374 | PR Newswire | UPPSALA, Sweden, March 6, 2026 /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&D Day on March 24, 2026. The... ► Artikel lesen | |
| 06.03. | Orexo changes the organizational structure and management team to increase focus on development of new products | 423 | PR Newswire | UPPSALA, Sweden, March 6, 2026 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces changes to its organizational structure and management... ► Artikel lesen | |
| 06.03. | Orexo AB: Orexo changes the organizational structure and management team to increase focus on development of new products | 198 | GlobeNewswire (Europe) | Uppsala, Sweden - March 6, 2026 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces changes to its organizational structure and management team. The changes are a result of the divestment of... ► Artikel lesen | |
| 19.02. | Orexo AB: Orexo: Conversion of Class C shares into ordinary shares and conveyance of ordinary shares within the framework of long-term performance-based incentive programs | 401 | GlobeNewswire (Europe) | The Board of Orexo AB (publ) has today decided to convert 416,417 Class C shares into ordinary shares and to subsequently convey 416,417 ordinary shares to certain participants in the long-term incentive... ► Artikel lesen | |
| 05.02. | Orexo AB: Orexo Interim Report Q4 2025, incl. Full Year Report | 539 | GlobeNewswire (Europe) | Turning a transformative deal into new opportunitiesQ4 2025 highlights›Dexcel Pharma USA aquired all rights to Zubsolv® US on December 31, at a purchase price of USD 91 m plus the value of inventory... ► Artikel lesen | |
| 22.12.25 | Orexo AB: Orexo Enters Into Agreement with Dexcel Pharma USA to Divest US Rights to Zubsolv | 493 | GlobeNewswire (Europe) | · An asset purchase agreement has been signed with Dexcel Pharma USA, which will acquire the full rights to Zubsolv® in the US, at a purchase price of USD 91 million plus the value of inventory at closing... ► Artikel lesen | |
| 23.10.25 | Orexo AB: Orexo Q3 2025 Interim Report | 246 | GlobeNewswire (Europe) | Unlocking the potential of the AmorphOX® technologyQ3 2025 highlights› Total net revenues of SEK 118.7 m (136.5)› EBITDA of SEK -9.8 m (-0.7), including a negative impact from costs associated with... ► Artikel lesen | |
| 01.10.25 | Orexo AB: Orexo strengthens innovation and research with move to new premises | 243 | GlobeNewswire (Europe) | Uppsala, Sweden, October 1, 2025 - Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY) is taking the next step in its development journey by relocating to new, modern premises in Uppsala Science Park. The move... ► Artikel lesen | |
| 29.09.25 | Orexo AB: Orexo US Awarded USD 8 Million by BARDA for OX390 Development Partnership | 473 | GlobeNewswire (Europe) | Uppsala, Sweden - September 29, 2025 - Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY), today announced its wholly owned US subsidiary, Orexo US, Inc., has been awarded USD 8 million in funding by the Biomedical... ► Artikel lesen | |
| 05.09.25 | Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication | 1.163 | PR Newswire | A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were... ► Artikel lesen | |
| 29.08.25 | Seminar: IP That Matters - Behind Orexo's Milestone Patent Win at the US Court | 492 | PR Newswire | UPPSALA, Sweden, Aug. 29, 2025 /PRNewswire/ -- Orexo (publ.), (STO: ORX) (OTCQX: ORXOY) in collaboration with its advisory international law firms Potter Clarkson LLP and Steptoe LLP, will... ► Artikel lesen | |
| 16.07.25 | Orexo AB: Orexo Q2 2025 Interim Report | 401 | GlobeNewswire (Europe) | 2025 outlook remains amid currency headwinds and non-recurring effectQ2 2025 highlights› Total net revenues of SEK 118.2 m (154.0), including a non-recurring rebate payment of SEK 8.9 m› EBITDA of SEK... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AURORA CANNABIS | 2,328 | -0,68 % | Aurora Cannabis Inc.: Aurora Cannabis Announces Full Year and Fiscal 2026 Fourth Quarter Results with Record Annual Revenue and Adjusted EBITDA | NASDAQ | TSX: ACB
Achieves Record Annual Global Medical Cannabis Net Revenue1 of $288.6 million, representing 18% YoY growth
Delivers Record Annual Adjusted EBITDA1 of $53.8 million... ► Artikel lesen | |
| ABBVIE | 222,70 | -0,13 % | AbbVie setzt mit Apogee-Übernahme neuen Akzent im Wettlauf um Blockbuster-Biologika | AbbVie stärkt mit der geplanten Übernahme von Apogee Therapeutics seine Position im Markt für Immunologie-Biologika und vertieft damit eine ohnehin schon dominante Wettbewerbsstellung. Der Deal zielt... ► Artikel lesen | |
| TILRAY BRANDS | 3,765 | -0,40 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 03.07.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| BRISTOL-MYERS SQUIBB | 50,79 | +0,02 % | Novartis, Gilead Sciences und Co. investieren Milliarden - warum jetzt die nächste Generation der Zelltherapie beginnt | ||
| TEVA | 30,400 | 0,00 % | Teva Pharmaceutical Industries Ltd: Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results | Teva-discovered TEV-'408 targets IL-15, a key driver of vitiligo biology TEV-'408 showed improvement in skin pigmentation and was well-tolerated with no safety signals observed to dateNearly 75% of... ► Artikel lesen | |
| BAUSCH HEALTH | 4,378 | +1,67 % | Bausch Health Companies Inc: Bausch Health to release Q2 results July 29 | ||
| BIONANO GENOMICS | 1,135 | -0,44 % | Bionano Genomics: Bionano Announces Hiring of Chief Scientific Officer | SAN DIEGO, June 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a leader in genome analysis solutions, today announced the appointment of Alex Hastie, Ph.D., as its Chief Scientific... ► Artikel lesen | |
| OPKO HEALTH | 1,300 | -0,76 % | OPKO Health, Inc.: OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results | MIAMI, April 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the first... ► Artikel lesen | |
| JAGUAR HEALTH | 2,615 | -1,69 % | Jaguar Health, Inc. - 8-K, Current Report | ||
| KEENOVA THERAPEUTICS | - | - | Keenova Therapeutics: Keenova Reports First Quarter 2026 Financial Results | Strong First-Quarter Performance Driven by Acthar® Gel1 and XIAFLEX®2
Pipeline Development, Synergy Plan Remain on Track
Reaffirms 2026 Net Sales Guidance of $1.94... ► Artikel lesen | |
| AVALO THERAPEUTICS | 17,400 | +3,08 % | Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum | ||
| BAYER | 50,82 | -0,70 % | Paukenschlag, Kaufempfehlung und Kurschance! Renk, Bayer, Antimony Resources Aktie! | Erstellt und veröffentlicht im Auftrag von Antimony Resources Corp. Paukenschlag bei Antimony Resources. Basis für den Investmentcase war bisher die Chance, dass das Unternehmen in Kanada ein Weltklasse-Antimonprojekt... ► Artikel lesen | |
| MERCK KGAA | 141,75 | -0,74 % | Stimmung im Biotech-Sektor dreht sich - Milliardendeals, neue Plattformen und mehr Kapital | ||
| NOVO NORDISK | 43,430 | +0,01 % | Vorsicht bei Novo Nordisk! TUI feiert Comeback! Globex Mining Aktie besser als Barrick Mining! | Vorsicht bei Novo Nordisk! Analysten warnen, dass der Pharmariese auf eine Patentklippe zusteuert. Dem Konzern könnte so Milliarden verloren gehen. Ohne viel Aufsehen hat die Aktie in den vergangenen... ► Artikel lesen | |
| LB PHARMACEUTICALS | 34,290 | 0,00 % | Wolfe Research initiates LB Pharmaceuticals stock with outperform rating |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OREXO AB finden Sie auf Wallstreet Online.